Literature DB >> 11921367

Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis.

Larry Heimark1, Petia Shipkova, Jonathan Greene, Hanan Munayyer, Taisa Yarosh-Tomaine, Beth DiDomenico, Roberta Hare, Birendra N Pramanik.   

Abstract

A liquid chromatography/mass spectrometry (LC/MS) method for separation and characterization of ergosterol biosynthetic precursors was developed to study the effect of Posaconazole on sterol biosynthesis in fungi. Ergosterol biosynthetic precursors were characterized from their electron ionization mass spectra acquired by a normal-phase chromatography, particle beam LC/MS method. Fragment ions resulting from cleavage across the D-ring and an abundant M - 15 fragment ion were diagnostic for methyl substitution at C-4 and C-14. Comparison of the sterol profile in control and treated Candida albicans incubations showed depletion of ergosterol and accumulation of C-4 and C-14 methyl-substituted sterols following treatment with Posaconazole. These C-4 and C-14 methyl sterols are known to be incapable of sustaining cell growth. The results demonstrate that Posaconazole exerts its antifungal activity by inhibition of ergosterol biosynthesis. Furthermore, Posaconazole appears to disrupt ergosterol biosynthesis by inhibition of lanosterol 14alpha-demethylase. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11921367     DOI: 10.1002/jms.280

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  9 in total

1.  Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.

Authors:  Farkad Ezzet; David Wexler; Rachel Courtney; Gopal Krishna; Josephine Lim; Mark Laughlin
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

Authors:  Hanan K Munayyer; Paul A Mann; Andrew S Chau; Taisa Yarosh-Tomaine; Jonathan R Greene; Roberta S Hare; Larry Heimark; Robert E Palermo; David Loebenberg; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 3.  Posaconazole: An Update of Its Clinical Use.

Authors:  Simon Leung; Mara N Poulakos; Jade Machin
Journal:  Pharmacy (Basel)       Date:  2015-10-21

4.  Insight into the Significance of Aspergillus fumigatus cyp51A Polymorphisms.

Authors:  Rocio Garcia-Rubio; Laura Alcazar-Fuoli; Maria Candida Monteiro; Sara Monzon; Isabel Cuesta; Teresa Pelaez; Emilia Mellado
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 5.  Fluconazole resistance in Candida species: a current perspective.

Authors:  Elizabeth L Berkow; Shawn R Lockhart
Journal:  Infect Drug Resist       Date:  2017-07-31       Impact factor: 4.003

6.  Genomic Multiplication and Drug Efflux Influence Ketoconazole Resistance in Malassezia restricta.

Authors:  Minji Park; Yong-Joon Cho; Yang Won Lee; Won Hee Jung
Journal:  Front Cell Infect Microbiol       Date:  2020-04-30       Impact factor: 5.293

7.  Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.

Authors:  Jose A Vazquez
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

8.  Copper Availability Influences the Transcriptomic Response of Candida albicans to Fluconazole Stress.

Authors:  Elizabeth W Hunsaker; Chen-Hsin Albert Yu; Katherine J Franz
Journal:  G3 (Bethesda)       Date:  2021-04-15       Impact factor: 3.154

9.  Narrow mutational signatures drive acquisition of multidrug resistance in the fungal pathogen Candida glabrata.

Authors:  Ewa Ksiezopolska; Miquel Àngel Schikora-Tamarit; Reinhard Beyer; Juan Carlos Nunez-Rodriguez; Christoph Schüller; Toni Gabaldón
Journal:  Curr Biol       Date:  2021-10-25       Impact factor: 10.834

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.